BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36949711)

  • 21. [Application of serum markers in medullary thyroid carcinoma].
    Han XD; Lu RQ; Hu HY; Guo L
    Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Dec; 55(12):1468-1474. PubMed ID: 34963245
    [No Abstract]   [Full Text] [Related]  

  • 22. High CEA levels in a case of resected colorectal cancer: delayed diagnosis of metachronous medullary thyroid cancer.
    Chen SW; Chen YK
    World J Surg Oncol; 2017 Dec; 15(1):230. PubMed ID: 29284496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ultrasonographic Features of Medullary Thyroid Carcinoma: Do they Correlate with Pre and PostOperative Calcitonin Levels?
    Cho KE; Gweon HM; Park AY; Yoo MR; Kim J; Youk JH; Park YM; Son EJ
    Asian Pac J Cancer Prev; 2016; 17(7):3357-62. PubMed ID: 27509975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High Ratio of Early Postoperative Calcitonin to Preoperative Calcitonin Could be a Novel Indicator of Poor Prognosis in Patients with Biochemical Incomplete Responses in Sporadic Medullary Thyroid Cancer.
    Chen L; Sun W; Qian K; Guo K; Sun T; Wu YI; Wang Z
    Endocr Pract; 2020 Jul; 26(7):738-747. PubMed ID: 33471642
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Souteiro P; Gouveia P; Ferreira G; Belo S; Costa C; Carvalho D; Duarte H; Sampaio IL
    Endocrine; 2019 May; 64(2):322-329. PubMed ID: 30684230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Value of routine measurement of serum calcitonin concentrations in patients with nodular thyroid disease: A multicenter study.
    Papi G; Corsello SM; Cioni K; Pizzini AM; Corrado S; Carapezzi C; Fadda G; Baldini A; Carani C; Pontecorvi A; Roti E
    J Endocrinol Invest; 2006 May; 29(5):427-37. PubMed ID: 16794366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Medullary thyroid carcinoma].
    Tiedje V; Ting S; Dralle H; Schmid KW; Führer D
    Internist (Berl); 2015 Sep; 56(9):1019-31. PubMed ID: 26338063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum calcitonin negative medullary thyroid carcinoma: a systematic review of the literature.
    Trimboli P; Giovanella L
    Clin Chem Lab Med; 2015 Sep; 53(10):1507-14. PubMed ID: 25781697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utility of proGRP as a tumor marker in the medullary thyroid carcinoma.
    Parra-Robert M; Orois A; Augé JM; Halperin I; Filella X; Molina R
    Clin Chem Lab Med; 2017 Mar; 55(3):441-446. PubMed ID: 27754959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brain metastasis from calcitonin-negative medullary thyroid carcinoma.
    Baptista PF; Fonseca LCM; Carvalho AFC; Silva SNVD; Freitas CRO
    Ann Endocrinol (Paris); 2022 Aug; 83(4):258-260. PubMed ID: 35537523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders.
    Elisei R; Bottici V; Luchetti F; Di Coscio G; Romei C; Grasso L; Miccoli P; Iacconi P; Basolo F; Pinchera A; Pacini F
    J Clin Endocrinol Metab; 2004 Jan; 89(1):163-8. PubMed ID: 14715844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biomarker-based risk stratification for previously untreated medullary thyroid cancer.
    Machens A; Dralle H
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2655-63. PubMed ID: 20339026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. T Cells Engineered to Express Immunoreceptors Targeting the Frequently Expressed Medullary Thyroid Cancer Antigens Calcitonin, CEA, and RET M918T.
    Erickson TA; Shih YP; Fass J; Jang M; Tran E
    Thyroid; 2022 Jul; 32(7):789-798. PubMed ID: 35587601
    [No Abstract]   [Full Text] [Related]  

  • 34. THE COMBINED USE OF CALCITONIN DOUBLING TIME AND
    Yang JH; Camacho CP; Lindsey SC; Valente FOF; Andreoni DM; Yamaga LY; Wagner J; Biscolla RPM; Maciel RMB
    Endocr Pract; 2017 Aug; 23(8):942-948. PubMed ID: 28614009
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinicopathological analysis of superior mediastinal lymph node metastases in medullary thyroid carcinoma].
    He YY; Chen YT; Wang J; Chen MQ; Zhu YM; Ni S; Liu SY
    Zhonghua Zhong Liu Za Zhi; 2023 Jan; 45(1):82-87. PubMed ID: 36709124
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical review: Incidentally discovered medullary thyroid cancer: diagnostic strategies and treatment.
    Ahmed SR; Ball DW
    J Clin Endocrinol Metab; 2011 May; 96(5):1237-45. PubMed ID: 21346073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Time to calcitonin normalization after surgery for node-negative and node-positive medullary thyroid cancer.
    Machens A; Lorenz K; Dralle H
    Br J Surg; 2019 Mar; 106(4):412-418. PubMed ID: 30725475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma.
    Pacini F; Fontanelli M; Fugazzola L; Elisei R; Romei C; Di Coscio G; Miccoli P; Pinchera A
    J Clin Endocrinol Metab; 1994 Apr; 78(4):826-9. PubMed ID: 8157706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum calcitonin-negative medullary thyroid carcinoma: role of CgA and CEA as complementary markers.
    Giovanella L; Crippa S; Cariani L
    Int J Biol Markers; 2008; 23(2):129-31. PubMed ID: 18629788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preoperative calcitonin testing improves the diagnosis of medullary thyroid carcinoma in female and male patients.
    Weber T; Poplawski A; Vorländer C; Dotzenrath C; Ringelband R; Schabram J; Passler C; Zielke A; Schlegel N; Nies C; Krenz D; Jähne J; Schwab R; Bartsch DK; Binnebösel M; Kemen M; Klinger C; Buhr H; Lorenz K
    Eur J Endocrinol; 2022 Jan; 186(2):223-231. PubMed ID: 34871180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.